• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arvinas Inc. (Amendment)

    2/14/24 5:24:02 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email
    SC 13G/A 1 arvn13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Arvinas, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    04335A105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 6,800,493
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,800,493

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,800,493

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     
     

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 6,800,493
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,800,493

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,800,493

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     
     

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power 6,422,250
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 6,422,250

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,422,250

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.4%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     
     

     

    Item1.
    (a)Name of Issuer

    Arvinas, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    5 Science Park, 395 Winchester Ave., New Haven, CT 06511

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 04335A105.
     
     

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The shares reported by the Filers in this Schedule 13G consist of 6,726,491 shares of Common Stock held by Qualified Fund and other private investment funds managed by EcoR1 and 3,422,380 shares of Common Stock issuable to those funds pursuant to pre-funded warrants issued by the Issuer, which warrants are subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 67,999,007 shares of Common Stock outstanding as of November 28, 2023, as reported in the Issuer’s Form 10-Q filed on December 8, 2023.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     
     

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 14, 2024

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

    Get the next $ARVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    3/11/2025Outperform → Perform
    Oppenheimer
    12/10/2024$69.00Buy
    BTIG Research
    11/18/2024$55.00Overweight
    Stephens
    More analyst ratings

    $ARVN
    Financials

    Live finance-specific insights

    See more
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

      2/11/25 7:00:04 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

      – ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is

      4/28/25 6:45:37 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berkowitz Noah sold $74,372 worth of shares (8,658 units at $8.59), decreasing direct ownership by 7% to 110,023 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      3/19/25 8:06:56 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Loomis David K sold $20,334 worth of shares (1,214 units at $16.75), decreasing direct ownership by 6% to 18,863 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      2/25/25 6:37:50 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cacace Angela M sold $70,238 worth of shares (4,207 units at $16.70), decreasing direct ownership by 4% to 97,231 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      2/25/25 6:35:35 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    SEC Filings

    See more

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Arvinas Inc.

      10-Q - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 5:16:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 7:05:21 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.

      SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)

      4/30/25 10:58:51 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Truist with a new price target

      Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

      5/5/25 8:28:44 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by TD Cowen

      TD Cowen downgraded Arvinas from Buy to Hold

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Jefferies with a new price target

      Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

      7/30/24 7:00:00 AM ET
      $ARVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

      - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

      6/24/24 4:37:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 1:22:38 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 7:00:23 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      9/10/24 10:30:07 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care